• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对严重急性呼吸综合征冠状病毒2型主要蛋白酶的腈类和炔类共价抑制剂的作用机制见解

Mechanistic Insights into Nitrile and Alkyne Covalent Inhibitors of the SARS-CoV-2 Main Protease.

作者信息

Nandi Ashim, Asadi Mojgan, Zhang Aoxuan, Chu Zhen T, Warshel Arieh

机构信息

Department of Chemistry, University of Southern California, Los Angeles, California 90089-1062, United States.

Department of Chemistry, Stanford University, Stanford, California 94305-5012, United States.

出版信息

ACS Catal. 2025 Jan 17;15(2):1158-1169. doi: 10.1021/acscatal.4c06020. Epub 2025 Jan 5.

DOI:10.1021/acscatal.4c06020
PMID:40933671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12419483/
Abstract

The treatment of SARS-CoV-2 can be accomplished by effective suppression of its 3CL protease (3CL), also known as the main protease (M) and nonstructural protein 5 (nsp5). Covalent inhibitors can irreversibly and selectively disable the protease, particularly when they are highly exothermic. Herein we investigated the distinct kinetic behaviors exhibited by two covalently linked SARS-CoV-2 inhibitors. One of these inhibitors features a nitrile reactive group, while the other has this group replaced by an alkyne group, a less reactive electrophile. Our investigations involve the assessment of the free energy surfaces of the key feasible mechanisms: that is, direct and water-assisted mechanisms involved in the rate-determining proton-transfer nucleophilic attack step through the utilization of both ab initio and empirical valence bond (EVB) simulations. The calculated free energy profiles show that substituting the nitrile group with alkyne increases the chemical barrier but leads to very exothermic reaction energy and is an irreversible process as opposed to nitrile, which is moderately exothermic and reversible. We also examine the time dependence of IC50 inhibition by applying an innovative kinetic simulation approach, which is particularly important in studies of covalent inhibitors with a very exothermic bonding step. Our computational approach provides a good agreement between the calculated and observed values of the time dependence results for the nitrile and alkyne inhibitors. Our approach, which is rather unique in combining calculations of the chemical barriers and the binding energy is likely to be very effective in studies of the effectiveness of other covalent inhibitors related cases.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的治疗可通过有效抑制其3C样蛋白酶(3CL)来实现,该蛋白酶也被称为主要蛋白酶(M)和非结构蛋白5(nsp5)。共价抑制剂可以不可逆地、选择性地使该蛋白酶失活,尤其是当它们具有高放热性时。在此,我们研究了两种共价连接的SARS-CoV-2抑制剂所表现出的不同动力学行为。其中一种抑制剂具有腈反应基团,而另一种则将该基团替换为炔基,炔基是一种反应性较低的亲电试剂。我们的研究涉及对关键可行机制的自由能面进行评估:即通过利用从头算和经验价键(EVB)模拟,在速率决定质子转移亲核攻击步骤中涉及的直接和水辅助机制。计算得到的自由能剖面图表明,用炔基取代腈基会增加化学势垒,但会导致非常放热的反应能量,并且是一个不可逆过程,而腈基则是中等放热且可逆的。我们还通过应用一种创新的动力学模拟方法来研究IC50抑制的时间依赖性,这在研究具有非常放热键合步骤的共价抑制剂时尤为重要。我们的计算方法在腈基和炔基抑制剂的时间依赖性结果的计算值和观测值之间提供了良好的一致性。我们的方法在结合化学势垒和结合能计算方面相当独特,可能在研究其他共价抑制剂相关情况的有效性方面非常有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/1288fe0fe9f1/nihms-2105225-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/a16740cdb998/nihms-2105225-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/f2313c2b119f/nihms-2105225-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/dc5d8054bdf0/nihms-2105225-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/539938258042/nihms-2105225-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/f4af617e1585/nihms-2105225-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/ac127fc4b469/nihms-2105225-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/5cac8ed1a2ea/nihms-2105225-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/6515859fa9b8/nihms-2105225-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/9babcc75e4e2/nihms-2105225-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/1e970ed7762f/nihms-2105225-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/c61c2757145a/nihms-2105225-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/1288fe0fe9f1/nihms-2105225-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/a16740cdb998/nihms-2105225-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/f2313c2b119f/nihms-2105225-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/dc5d8054bdf0/nihms-2105225-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/539938258042/nihms-2105225-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/f4af617e1585/nihms-2105225-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/ac127fc4b469/nihms-2105225-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/5cac8ed1a2ea/nihms-2105225-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/6515859fa9b8/nihms-2105225-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/9babcc75e4e2/nihms-2105225-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/1e970ed7762f/nihms-2105225-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/c61c2757145a/nihms-2105225-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/533e/12419483/1288fe0fe9f1/nihms-2105225-f0013.jpg

相似文献

1
Mechanistic Insights into Nitrile and Alkyne Covalent Inhibitors of the SARS-CoV-2 Main Protease.对严重急性呼吸综合征冠状病毒2型主要蛋白酶的腈类和炔类共价抑制剂的作用机制见解
ACS Catal. 2025 Jan 17;15(2):1158-1169. doi: 10.1021/acscatal.4c06020. Epub 2025 Jan 5.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Short-Term Memory Impairment短期记忆障碍
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Aspects of Genetic Diversity, Host Specificity and Public Health Significance of Single-Celled Intestinal Parasites Commonly Observed in Humans and Mostly Referred to as 'Non-Pathogenic'.人类常见且大多被称为“非致病性”的单细胞肠道寄生虫的遗传多样性、宿主特异性及公共卫生意义
APMIS. 2025 Sep;133(9):e70036. doi: 10.1111/apm.70036.
6
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
7
Elbow Fractures Overview肘部骨折概述
8
Sexual Harassment and Prevention Training性骚扰与预防培训
9
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
10
Omega-3 fatty acids for depression in adults.成人抑郁症的ω-3脂肪酸治疗
Cochrane Database Syst Rev. 2015 Nov 5;2015(11):CD004692. doi: 10.1002/14651858.CD004692.pub4.

本文引用的文献

1
Assessing the Catalytic Role of Native Glucagon Amyloid Fibrils.评估天然胰高血糖素淀粉样纤维的催化作用。
ACS Catal. 2024 Apr 5;14(7):4656-4664. doi: 10.1021/acscatal.4c00452. Epub 2024 Mar 13.
2
Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design.新冠病毒主蛋白酶的多个氧化还原开关为药物设计提供了机会。
Nat Commun. 2024 Jan 9;15(1):411. doi: 10.1038/s41467-023-44621-0.
3
Landscape of Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery.
蛋白质共价修饰建模工具全景:计算共价药物发现综述。
J Phys Chem B. 2023 Nov 16;127(45):9663-9684. doi: 10.1021/acs.jpcb.3c04710. Epub 2023 Nov 3.
4
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.新型冠状病毒主蛋白酶抑制剂的最新进展:从奈玛特韦到未来展望。
Biomolecules. 2023 Sep 2;13(9):1339. doi: 10.3390/biom13091339.
5
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.炔烃作为潜伏弹头共价靶向 SARS-CoV-2 主要蛋白酶。
J Med Chem. 2023 Sep 14;66(17):12237-12248. doi: 10.1021/acs.jmedchem.3c00810. Epub 2023 Aug 18.
6
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.探索多样化的反应弹头以设计 SARS-CoV-2 主蛋白酶抑制剂。
Eur J Med Chem. 2023 Nov 5;259:115667. doi: 10.1016/j.ejmech.2023.115667. Epub 2023 Jul 19.
7
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.含奈玛特韦的 SARS-CoV-2 主蛋白酶抑制剂的炔衍生物通过与亲核半胱氨酸发生共价反应来抑制。
J Med Chem. 2023 Feb 23;66(4):2663-2680. doi: 10.1021/acs.jmedchem.2c01627. Epub 2023 Feb 9.
8
Paxlovid Information From FDA and Guidance for AES Members.来自美国食品药品监督管理局(FDA)的帕罗韦德信息及对美国急诊医师协会(AES)成员的指导意见
Epilepsy Curr. 2022 Apr 4;22(3):201-204. doi: 10.1177/15357597221088415. eCollection 2022 Jun.
9
Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection.使用奈玛特韦及其衍生物对抗新型冠状病毒感染的进展与挑战。
J Pharm Anal. 2023 Mar;13(3):255-261. doi: 10.1016/j.jpha.2022.10.005. Epub 2022 Nov 2.
10
Exploring the Role of Chemical Reactions in the Selectivity of Tyrosine Kinase Inhibitors.探索化学反应在酪氨酸激酶抑制剂选择性中的作用。
J Am Chem Soc. 2022 Sep 14;144(36):16638-16646. doi: 10.1021/jacs.2c07307. Epub 2022 Aug 31.